LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Advair | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Databases & Libraries | Drugs & Pharmacology | Flonase | Pneumonia | Spiriva | Study | Symbicort | Tiotropium